(ATYR) aTyr Pharma, Inc. Business Model Canvas Research

aTyr Pharma, Inc. uses CROs and specialist service vendors to run its Phase III and Phase 1b/2a programs, especially for clinical operations, data management, and monitoring. This model lets the Company add late-stage trial capacity without building every function in-house, which is critical when multiple study teams and sites must stay aligned.

• Supports Phase III execution
• Handles data and site monitoring
• Lowers in-house build needs

aTyr Pharma’s manufacturing and supply partners are critical because its protein-based, clinical-stage biologics need GMP production, validated release testing, and tight drug-supply logistics for preclinical work and trials. These partners help keep batches consistent, preserve quality, and reduce the risk of trial delays when small changes can stop a study.

• GMP manufacturing supports trial readiness
• Supply partners manage clinical dosing logistics
• Consistency lowers batch-to-batch risk
• Preclinical and trial supply stays on schedule

aTyr Pharma, Inc. is using preclinical fibrosis research to advance ATYR0101, a fusion protein derived from aspartyl-tRNA synthetase, toward lead selection and IND-enabling studies. This work is the key filter stage: it helps narrow the best candidate before human testing and lowers downstream development risk.

• ATYR0101 is the core fibrosis asset
• Protein is based on aspartyl-tRNA synthetase
• Preclinical data guides candidate selection
• Supports IND-enabling steps next

aTyr Pharma is advancing ATYR0750 for liver disorders, building on its tRNA synthetase biology platform. The candidate is derived from alanyl-tRNA synthetase, and this move extends the pipeline beyond lung and fibrosis programs into a wider organ-disease franchise.

• ATYR0750 targets liver disorders
• Derived from alanyl-tRNA synthetase
• Broadens beyond lung and fibrosis

aTyr Pharma, Inc.’s tRNA synthetase domain know-how is the core of its discovery engine: it has programs built from aspartyl-tRNA synthetase and alanyl-tRNA synthetase domains, which it uses to design proprietary molecules and widen the pipeline. As of FY2025, aTyr Pharma, Inc. reported no product revenue and continued to fund this platform through R&D spending.

• Domain-based discovery drives new molecules.
• AsnRS and AlaRS-derived programs anchor the pipeline.
• Platform supports pipeline expansion.

aTyr Pharma’s key resource here is clinical and regulatory know-how: running Phase III and Phase 1b/2a trials takes tight clinical operations, safety monitoring, regulatory filing, and data review teams. For a development-stage biopharma, this expertise is the core asset that turns aTyr’s pipeline into testable, FDA-ready evidence.

• Phase III needs disciplined trial execution.
• Safety and data review must stay constant.
• Regulatory teams support FDA alignment.

ATYR0101 adds fibrosis optionality because it is in preclinical development for a disease area that still has no approved therapy in many organs. Fibrosis drives about 45% of all deaths in developed countries, so even a second shot outside lung inflammation can widen aTyr Pharma, Inc.’s commercial path.

• Preclinical ATYR0101
• Big unmet fibrosis need
• Second revenue angle

The Kyorin agreement gives aTyr Pharma, Inc. a clear path to Japanese development and commercialization, so efzofitimod can reach the ILD market faster through a local partner. Japan’s ~125 million people make this access meaningful, and local execution should fit payer, regulatory, and physician needs better than a remote model.

• Local Japan pathway via Kyorin
• Faster regional entry for efzofitimod
• Better fit for ILD launch needs

aTyr Pharma keeps formal, evidence-based contact with regulators to secure trial approvals, amendment reviews, and a clear path to filing for efzofitimod. For a development-stage biotech, this is continuous work, since every protocol change and future submission must align with FDA and other agencies.

• Formal, ongoing regulator contact
• Supports trial approvals and amendments
• Builds submission pathway evidence

aTyr Pharma, Inc. relies on SEC filings, press releases, and earnings updates to keep public investors informed, which matters because the Company is still pre-revenue or near-revenue and must support future funding with clear trial and cash updates. In biopharma, trust in disclosure can shape capital access as much as pipeline data.

• SEC filings drive investor trust
• Clear trial updates support funding
• Pre-revenue status raises disclosure needs

aTyr Pharma, Inc. uses press releases and SEC filings to share clinical and corporate updates, keeping investors, partners, and the scientific community aligned on trial progress. These disclosures matter because they turn pipeline milestones into market-facing data, from 10-Q and 10-K filings to safety and efficacy readouts.

One public data trail, one market message.

• Press releases: trial and pipeline news
• SEC filings: 10-Q, 10-K, 8-K updates
• Audience: investors, partners, scientists

aTyr Pharma, Inc.’s corporate website is the main direct channel for pipeline and partnership details, with efzofitimod as its lead clinical program. It centralizes company background, SEC filings, and program updates in one place, making it easy for investors, researchers, and potential collaborators to track aTyr Pharma, Inc. in real time.

• Lead asset: efzofitimod

• One source for updates and filings

Specialist physicians, led by pulmonologists, are aTyr Pharma, Inc.'s key gatekeepers for lung disease. They diagnose sarcoidosis, recruit patients into trials, and would be the first prescribers of efzofitimod; sarcoidosis affects about 175,000-200,000 people in the U.S., so this segment shapes both trial speed and future uptake.

• Pulmonologists drive diagnosis and referral.
• They enroll patients and guide trial design.
• They are the likely first prescribers.

aTyr Pharma, Inc.’s future customer base could expand into fibrosis and liver disease if ATYR0101 and ATYR0750 succeed. Fibrosis affects millions across organs, and liver disease is a large pool: the CDC says about 4.5 million U.S. adults have diagnosed liver disease, so these programs could add patients beyond the lead ILD franchise.

• ATYR0101: fibrosis patients
• ATYR0750: liver disorder patients
• Longer-term, post-ILD expansion

aTyr Pharma, Inc. must fund IND-enabling work, trial reporting, and FDA submission prep, so regulatory spend rises as each program moves from Phase 1 to Phase 3. In FY2025, the FDA’s standard human drug application fee was $4,310,350, while quality systems and GxP controls add recurring overhead even before approval.

• IND, trial, and filing support costs are mandatory
• Quality systems and compliance never stop
• Costs rise with each clinical stage

aTyr Pharma, Inc. must fund finance, legal, HR, and investor relations to meet U.S. public-company rules and keep Nasdaq/SEC reporting on track. These general and administrative costs also support partner talks, contract work, and corporate governance, so they stay core even when R&D shifts quarter to quarter.

• Finance and SEC reporting
• Legal and HR support
• Investor relations
• Partnering and governance

If aTyr Pharma, Inc. gets efzofitimod approved and sold, product sales could become a real revenue stream. Right now it is still investigational, and aTyr Pharma, Inc. reported $0 product revenue in its latest filed annual results, so this stream is not yet established.

• Depends on FDA and other market approvals
• Revenue starts only after launch
• Current sales are still zero

Additional licensing deals could monetize atyr Pharma, Inc.’s pipeline beyond efzofitimod, with ATYR0101 and ATYR0750 as the most obvious partnering candidates. In biopharma, out-licensing is a standard cash path, and atyr Pharma, Inc. could use it to add non-dilutive revenue, which matters because 2025 revenue was still concentrated in one lead program.

• ATYR0101 and ATYR0750 can attract partners
• Licensing adds non-dilutive cash
• Diversifies revenue away from efzofitimod